Phaseolamin, a protein extract derived from white kidney beans (Phaseolus vulgaris), has been studied for its potential to support fat metabolism, though its primary mechanism is through inhibition of alpha-amylase, an enzyme involved in carbohydrate digestion. By inhibiting alpha-amylase, phaseolamin reduces the breakdown and absorption of dietary starches, thereby potentially lowering calorie intake and contributing indirectly to weight management. While some small clinical studies and trials suggest that supplementation with phaseolamin may result in modest reductions in body weight and waist circumference, these effects are predominantly attributed to decreased carbohydrate absorption rather than direct effects on fat metabolism.

Evidence specifically linking phaseolamin to support or treatment of poor fat metabolism is limited. Most available research focuses on its carbohydrate-blocking properties, with only a few studies indicating slight improvements in lipid profiles (e.g., reductions in triglycerides or LDL cholesterol) that may accompany weight loss. These findings are not consistent or robust enough to firmly establish phaseolamin as a direct modulator of fat metabolism. Therefore, while some scientific evidence exists for weight management and related metabolic outcomes, the level of evidence supporting its use specifically for poor fat metabolism is limited and should be interpreted cautiously.

In summary, phaseolamin's primary validated use is as a carbohydrate absorption inhibitor, and its role in fat metabolism is indirect and not strongly supported by current scientific literature.